The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
5-Amino-2-hydroxybenzoic Acid 4-(5-Thioxo-5 H-[1,2]dithiol-3yl)-phenyl Ester (ATB-429), a Hydrogen Sulfide-Releasing Derivative of Mesalamine, Exerts Antinociceptive Effects in a Model of Postinflammatory Hypersensitivity
Abstract
H(2)S functions as a neuromodulator and exerts anti-inflammatory activities. Recent data indicate that irritable bowel syndrome (IBS) is linked to inflammation of the gastrointestinal tract. In this study, we have investigated the role of a novel H(2)S-releasing derivative of mesalamine (5-amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester, ATB-429) in modulating nociception to colorectal distension (CRD), a model that mimics some features of IBS, in healthy and postcolitic rats. Four graded (0.4-1.6 ml of water) CRDs were produced in conscious rats, and colorectal sensitivity and pain were assessed by measuring the abdominal withdrawal response and spinal c-Fos expression. In healthy rats, ATB-429 dose dependently (25, 50, or 100 mg/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal c-FOS mRNA, whereas mesalamine had no effect. ATB-429-induced antinociception was reversed by glibenclamide, a ATP-sensitive K(+) (K(ATP)) channel inhibitor. The antinociceptive effect of ATB-429 was maintained in a rodent model of postinflammatory hypersensitivity (4 weeks after colitis induction). At a dose of 100 mg/kg, ATB-429 reversed the allodynic response caused by CRD in postcolitic rats. Colonic cyclooxygenase-2 and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by ATB-429, but not by mesalamine. ATB-429, but not mesalamine, increased blood concentrations of H(2)S in both healthy and postcolitic rats. Taken together, these data suggest that ATB-429 inhibits hypersensitivity induced by CRD in both healthy and postcolitic, allodynic rats by a K(ATP) channel-mediated mechanism. This study provides evidence that H(2)S-releasing drugs might have beneficial effects in the treatment of painful intestinal disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, mesalamine 3.2 g/day for 12 wk (168) and prednisolone 30 mg/day for 3 wk (52) were not effective in improving the GI symptoms in patients with PI-IBS.”
From Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome (2013) · cites this paper as [52]
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
The possible role of hydrogen sulfide as an endogenous neuromodulator
Abe, K., & Kimura, H. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-03-01066.1996 · Cited by 2,240
The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener
Zhao, W., Zhang, J., Lu, Y., & Wang, R. (2001) · The EMBO Journal · doi:10.1093/emboj/20.21.6008 · Cited by 1,936
Two's company, three's a crowd: can H 2 S be the third endogenous gaseous transmitter?
Wang, R. T. (2002) · The FASEB Journal · doi:10.1096/fj.02-0211hyp · Cited by 1,808
Barbara, G., Stanghellini, V., De Giorgio, R., Cremon, C., Cottrell, G. S., Santini, D., Pasquinelli, G., Morselli-Labate, A. M., Grady, E. F., Bunnett, N. W., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.055 · Cited by 1,475
Hydrogen sulfide is a novel mediator of lipopolysaccharide‐induced inflammation in the mouse
Li, L., Bhatia, M., Zhu, Y. Z., Zhu, Y. C., Ramnath, R. D., Wang, Z. J., Anuar, F., Whiteman, M., Salto‐Tellez, M., & Moore, P. K. (2005) · The FASEB Journal · doi:10.1096/fj.04-3583fje · Cited by 773
Al–Chaer, E. D., Kawasaki, M., & Pasricha, P. J. (2000) · Gastroenterology · doi:10.1053/gast.2000.19576 · Cited by 727
Visceral pain: a review of experimental studies
Ness, T. J., & Gebhart, G. F. (1990) · Pain · doi:10.1016/0304-3959(90)90021-5 · Cited by 605
Cytokines in intestinal inflammation: Pathophysiological and clinical considerations
Sartor, R. B. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90614-9 · Cited by 595
The Pharmacology of ATP-Sensitive Potassium Channels
Edwards, G., & Weston, A. H. (1993) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.33.040193.003121 · Cited by 529
Cited by
Sorted by citations
Hydrogen sulphide and its therapeutic potential
Szabó, C. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2425 · Cited by 2,039
Physiological Implications of Hydrogen Sulfide: A Whiff Exploration That Blossomed
Wang, R. (2012) · Physiological Reviews · doi:10.1152/physrev.00017.2011 · Cited by 1,962
Chemical Biology of H 2 S Signaling through Persulfidation
Filipović, M. R., Živanović, J., Álvarez, B., & Banerjee, R. V. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00205 · Cited by 1,059
Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter
Wallace, J. L., & Wang, R. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4433 · Cited by 882
Self-citationHydrogen sulfide as a gasotransmitter
Gadalla, M. M., & Snyder, S. H. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06580.x · Cited by 493
Metadata
- Authors
- Distrutti, E., Sediari, L., Mencarelli, A., Renga, B., Orlandi, S., Russo, G., Caliendo, G., Santagada, V., Cirino, G., Wallace, J. L., & Fiorucci, S.
- Affiliations
- University of Perugia (IT)
- ORCID
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2006-10
- Volume
- 319
- Issue
- 1
- Pages
- 447-458
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2166470604
- Cited by
- 144
- References
- 41
- Citations by year
- 2026: 2 · 2024: 4 · 2023: 2 · 2022: 9 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 6 · 2016: 5 · 2015: 12 · 2014: 13 · 2013: 14 · 2012: 6
- FWCI
- 9.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Sulfur Compounds in Biology
- Keywords
- hydrogen sulfide, 5-aminosalicylic acid, irritable bowel syndrome, colorectal distension, antinociception, ATP-sensitive potassium channels, glibenclamide, Fos expression, cyclooxygenase-2, IL-1β, colitis, allodynia, visceral pain, neuromodulation
- MeSH terms
- Analgesics, Animals, Colon, Disulfides, Hydrogen Sulfide, Male, Spinal Cord, Rats, Wistar, Mesalamine, Potassium Channel Blockers, Irritable Bowel Syndrome, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
